stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) EPS (diluted)
Harmony Biosciences Holdings, Inc.'s EPS (diluted) for fiscal 2025 was $2.71, up 7.97% from $2.51 in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.02. Over the past ten years it has ranged from −$24.07 (fiscal 2019) to $2.97 (fiscal 2022); the current reading is higher than 88% of that period. Harmony Biosciences Holdings, Inc. ranks 20th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.71 | 7.97% |
| FY2024 | $2.51 | 17.84% |
| FY2023 | $2.13 | (28.28%) |
| FY2022 | $2.97 | 412.07% |
| FY2021 | $0.58 | — |
| FY2020 | −$2.48 | — |
| FY2019 | −$24.07 | — |
| FY2018 | −$1.10 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.81 | (36.91%) |
| Jun 2026 | $1.28 | 132.73% |
| Mar 2026 | $0.55 | 44.74% |
| Dec 2025 | $0.38 | (56.32%) |
| 25 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. | $3.02 |
| TRVI Trevi Therapeutics, Inc. compare | −$0.34 |
| FTRE Fortrea Holdings Inc. compare | −$0.73 |
| MESO Mesoblast Limited compare | −$1.12 |
| VIR Vir Biotechnology, Inc. compare | −$1.26 |
| SRPT Sarepta Therapeutics, Inc. compare | −$1.37 |
| MAZE Maze Therapeutics, Inc. compare | −$2.52 |
| REPL Replimune Group, Inc. compare | −$2.79 |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$5.17 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item